©2024 Stanford Medicine
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Recruiting
Trial ID: NCT03532542
Purpose
The main objective of this study is to evaluate the safety and tolerability of long-term
treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Official Title
Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen
Stanford Investigator(s)
John W. Day, MD, PhD
Professor of Neurology (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology
Eligibility
Inclusion Criteria:
- Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
- Is between 7 and 23 years of age, inclusive, at enrollment.
Other inclusion/exclusion criteria apply.
Intervention(s):
drug: Casimersen
drug: Golodirsen
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305